MedPage Today on MSN

Ultra-Rare Mitochondrial Disease Gets First FDA-Approved Drug

The FDA approved doxecitine and doxribtimine powder (Kygevvi) for thymidine kinase 2 deficiency (TK2d), an ultra-rare ...
pharmaphorum

UCB bags FDA okay for first drug to treat rare disease TK2d

That research led to the FDA granting compassionate use of the doxecitine and doxribtimine treatment in Arturito Estopinan, ...
Veritasium on MSN

How UV Causes Cancer and Aging

Ultraviolet light causes damage to DNA, leads to cancer and photoaging: age spots and wrinkles. I was curious about this ...
GlobalData on MSN

FDA approves UCB’s Kygevvi for genetic mitochondrial disease

The approval was based on data from a Phase II trial, two retrospective chart review studies and an expanded access programme ...
Fierce Pharma

On a roll, UCB picks up another rare disease FDA approval

UCB has scored an FDA approval for ultra-rare disease treatment Kygevvi, continuing the positive momentum for the Belgian ...
Pulmonology Advisor

FDA Approves Kygevvi for Thymidine Kinase 2 Deficiency

The FDA has approved Kygevvi (doxecitine and doxribtimine) for the treatment of TK2d in adults and pediatric patients with an age of symptom onset on or before 12 years.
GEN - Genetic Engineering and Biotechnology News

FDA Approves First Treatment for Rare Thymidine Kinase 2 Deficiency

FDA approved KYGEVVI, the first and only treatment of thymidine kinase 2 deficiency (TK2d) in adults and pediatric patients.
Medscape

Multi-omics Profiling Makes Distinctions Between ACPA-Negative and ACPA-Positive Rheumatoid Arthritis

An observational cohort study uses multi-omics profiling to identify distinct biomarkers that could aid in the earlier ...
Applied Clinical Trials Online

FDA Approves UCB’s Kygevi for TK2 Deficiency Based on Multi-Study Clinical Program Demonstrating Significant Survival and Motor Gains

Kygevi (doxecitine and doxribtimine) earned FDA approval as the first treatment for thymidine kinase 2 deficiency, supported by data from a Phase II trial and multiple retrospective studies showing ...
Medindia

U.S. FDA approves KYGEVVI® (doxecitine and doxribtimine), the first and only treatment for adults and children living with thymidine kinase 2 deficiency (TK2d)

UCB (Euronext Brussels: UCB), a global biopharmaceutical company, today announced that KYGEVVI® has been granted approval by the U.S. Food and Drug Administration (FDA) for the treatment of adults and ...
BioWorld

Metsera in the middle of Novo, Pfizer bidding war

Pfizer Inc. upped its original $7.3 billion September offer to buy Metsera Inc., but the obesity specialist maintained that a now-improved unsolicited bid by semaglutide developer Novo Nordisk A/S is ...